Oncologic emergencies secondary to advanced colorectal cancer successfully treated with oxaliplatin/5-fluorouracil/leucovorin: Report of three cases

被引:1
|
作者
Cavanna, L [1 ]
Bertè, R [1 ]
Bidin, L [1 ]
Civardi, G [1 ]
Anselmi, E [1 ]
Lazzaro, A [1 ]
Moroni, CF [1 ]
Palladino, MA [1 ]
Rodinò, C [1 ]
Vallisa, D [1 ]
机构
[1] Hosp Gugliemo Saliceto, Dept Med Oncol & Hematol, I-29100 Piacenza, Italy
关键词
advanced colorectal cancer; oncologic emergencies; oxaliplatin; 5-fluorouracil; leucovorin; FOLFOX-4;
D O I
10.1179/joc.2005.17.3.334
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Metastatic/advanced colorectal cancer is considered a resistant disease and oncologic emergencies secondary to advanced disease may be regarded with a nihilistic attitude. The objective of this report is to emphasize the efficacy of the oxaliplatin/5-fluorouracil/leucovorin regimen (FOLFOX-4) in three patients presenting oncologic emergencies secondary to advanced colon cancer. The first case was a 40-year-old man with severe respiratory insufficiency due to massive carcinomatous lymphangitis; subsequently a cecal adenocarcinoma was diagnosed. The patient's conditions became life-threatening and he was admitted to the intensive care unit. The second case was a 41-year-old woman presenting with fever, abdominal mass and pain. Ultrasound and CT-scan revealed two hepatic masses (13x15 and 15x20 cm), diagnosed as liver metastases from colon cancer. The patient's condition deteriorated with intestinal obstruction secondary to the large left liver mass. The third case was a 58-year-old woman presenting with hepatic mass, fever and weight loss. Ultrasound and CT-scan showed a liver lesion occupying the right lobe (12x14 cm). Ultrasonically-guided biopsy and colonoscopy showed liver metastases from cecal cancer. A 5-fluorouracil/leucovorin regimen failed to improve her clinical condition and she had disease progression, inferior vena cava neoplastic thrombosis and right hydronephrosis. All three patients rapidly improved after a few cycles of oxaliplatin-containing chemotherapy. These cases demonstrate that even patients with advanced colorectal cancer presenting with oncologic emergencies and life-threatening conditions can be successfully treated with the FOLFOX-4 regimen.
引用
收藏
页码:334 / 338
页数:5
相关论文
共 50 条
  • [31] Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: A pilot study
    Kwon, Hyuk-Chan
    Oh, Sung Yong
    Lee, Suee
    Kim, Sung-Hyun
    Kim, Hyo-Jin
    WORLD JOURNAL OF GASTROENTEROLOGY, 2007, 13 (46) : 6231 - 6235
  • [32] Bevacizumab plus infusional 5-fluorouracil,leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy:A pilot study
    Hyuk-Chan Kwon
    Sung Yong Oh
    Suee Lee
    Sung-Hyun Kim
    Hyo-Jin Kim
    World Journal of Gastroenterology, 2007, (46) : 6231 - 6235
  • [33] Hepatic arterial infusion of oxaliplatin, 5-fluorouracil and leucovorin in patients with liver metastases from colorectal carcinoma
    Melichar, B.
    Ferko, A.
    Krajina, A.
    Rouskova, L.
    Dvorak, J.
    Svebisova, H.
    Neoral, C.
    Koecher, M.
    Malirova, E.
    Paral, J.
    JOURNAL OF BUON, 2012, 17 (04): : 677 - 683
  • [35] Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies
    Cho, CD
    Fisher, GA
    Halsey, J
    Sikic, BI
    INVESTIGATIONAL NEW DRUGS, 2006, 24 (02) : 117 - 123
  • [36] Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies
    Cheryl D. Cho
    George A. Fisher
    Joanne Halsey
    Branimir I. Sikic
    Investigational New Drugs, 2006, 24 : 117 - 123
  • [37] Phase II study of oxaliplatin plus leucovorin and 5-fluorouracil in heavily pretreated metastatic breast cancer patients
    Sun, Si
    Wang, Lei Ping
    Zhang, Jian
    Yang, Xiao Yan
    Zhang, Qun Ling
    Jia, Zhen
    Hu, Xi Chun
    Wang, Bi Yun
    MEDICAL ONCOLOGY, 2012, 29 (02) : 418 - 424
  • [38] Paclitaxel, oxaliplatin, 5-fluorouracil and leucovorin combination chemotherapy in patients with recurrent or metastatic gastric cancer
    Lan, Yan-qin
    Wu, Ri-ping
    Huang, Xiao-bing
    Wang, Xin-li
    Zhong, Dong-ta
    Huang, Chuan-yong
    Song, Jin-tian
    TUMORI JOURNAL, 2018, 104 (01): : 22 - 29
  • [39] A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen
    Cecchin, E.
    D'Andrea, M.
    Lonardi, S.
    Zanusso, C.
    Pella, N.
    Errante, D.
    De Mattia, E.
    Polesel, J.
    Innocenti, F.
    Toffoli, G.
    PHARMACOGENOMICS JOURNAL, 2013, 13 (05) : 403 - 409
  • [40] Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis
    Liang Xiao-bo
    Hou Sheng-huai
    Li Yao-ping
    Wang Li-chun
    Zhang Xin
    Yang Jun
    CHINESE MEDICAL JOURNAL, 2010, 123 (22) : 3314 - 3318